STAAR Surgical names Andrew Pilon: Stifel target for STAAR Surgical stock is USD 31

Published on 10/20/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 93.54 million, up 111.1 percent year over year. STAAR Surgical stock costs EUR 19.56 on October 20, 2026.

Growth role and earnings calendar

STAAR Surgical appointed Andrew Pilon on October 8, 2026, expanding its business development leadership.
Second-quarter revenue reached USD 93.54 million, up 111.1 percent year over year.
STAAR Surgical stock trades at EUR 19.56 at 1:13 p.m. CEST at Lang & Schwarz on October 20, 2026.

STAA, US8523123052, Illustration mit AI erstellt.

STAAR Surgical (ISIN US8523123052) is priced at EUR 19.56 at Lang & Schwarz on October 20, 2026, at 1:13 p.m. CEST. The latest company move was the appointment of Andrew Pilon as vice president of business development on October 8, 2026, while Stifel had set a USD 31 price target on September 29, 2026.

A broader role for growth

According to STAAR Surgical, Pilon will work on strategic partnerships, innovation opportunities and the companys multi-product platform strategy. His previous experience included business development and transactions at Johnson & Johnson Vision and Bausch + Lomb.

The appointment follows a strong second quarter. Earnings Today reported that revenue for the quarter ended June 30, 2026, reached USD 93.53 million, up 111.1 percent from the prior year. GAAP earnings per share were USD 0.16, while net income reached USD 8.06 million.

What does the target imply?

Investing.com reported on September 29, 2026, that Stifel upgraded STAAR Surgical from Hold to Buy and raised its target from USD 28 to USD 31. The report linked the view to China growth, the EVO+ product mix and easier comparisons outside China.

The companys recent chronology is clear: second-quarter results on August 12, 2026, delivered USD 93.53 million in revenue; Stifel changed its view on September 29, 2026, with a USD 31 target; and STAAR Surgical appointed Pilon on October 8, 2026, for a role tied to strategic expansion.

Next date for results

Earnings Today lists November 4, 2026, as the scheduled date for the next quarterly report. That date is the next concrete event for investors tracking whether the recent revenue pace continues.

Price stays below recent highs

STAAR Surgical operates in medical instruments and supplies and sells implantable lenses for vision correction. Its primary listing is Nasdaq, and the company says it has sold more than 4 million ICLs in over 85 countries. The EUR 19.56 Lang & Schwarz indication gives the market a fresh reference point ahead of the November reporting date.

STAAR Surgical stock was trading at EUR 19.56 at Lang & Schwarz on October 20, 2026, at 1:13 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of STAAR Surgical stock.